Clinical trial data published by GW Pharmaceuticals suggests patients with brain tumors who are treated with cannabis extracts may increase their survival rates by a year in comparison to those who do not receive this treatment. Of the 21 patients with recurrent glioblastoma multiforme who were undergoing conventional anti-cancer treatments, some received a cannabis extract with both THC and CBD while others received placebo. The company stated in a press release, “[P]atients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients in the placebo cohort... Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group.”
Although these findings support other preclinical data suggesting a combination of cannabinoids and temozolomide is more effective in treating cancer than traditional therapies alone, we would like to see larger thorough clinical trials to confirm this data. This information has been provided by the Daily Chronic and approved by our Chief Medical Officer.